Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2006-05-22 15:12:16 UTC |
---|
Update Date | 2021-09-14 15:48:27 UTC |
---|
HMDB ID | HMDB0002873 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Deacetyldiltiazem |
---|
Description | Deacetyldiltiazem is a metabolite product of the drug Diltiazem (a coronary vasodilator), and is present in the plasma of individuals taking that medication. (PMID 2328299 ). The action mechanisms involved in the effect of Deacetyldiltiazem on blood rheological (erythrocyte deformation) properties appeared to be similar to Diltiazem, but different from other metabolites of this drug. (PMID 3411434 ). |
---|
Structure | COC1=CC=C(C=C1)[C@@H]1SC2=CC=CC=C2N(CCN(C)C)C(=O)[C@@H]1O InChI=1S/C20H24N2O3S/c1-21(2)12-13-22-16-6-4-5-7-17(16)26-19(18(23)20(22)24)14-8-10-15(25-3)11-9-14/h4-11,18-19,23H,12-13H2,1-3H3/t18-,19+/m1/s1 |
---|
Synonyms | Value | Source |
---|
Diltiazem | HMDB | Deacetyldiltiazem, (cis)-isomer | MeSH, HMDB | Desacetyldiltiazem | MeSH, HMDB | Deacetyldiltiazem hydrochloride, (cis-(+-))-isomer | MeSH, HMDB | Deacetyldiltiazem hydrochloride, (cis)-isomer | MeSH, HMDB | Deacetyldiltiazem hydrochloride, (trans)-isomer | MeSH, HMDB | Deacetyldiltiazem | MeSH |
|
---|
Chemical Formula | C20H24N2O3S |
---|
Average Molecular Weight | 372.481 |
---|
Monoisotopic Molecular Weight | 372.150763334 |
---|
IUPAC Name | (2S,3S)-5-[2-(dimethylamino)ethyl]-3-hydroxy-2-(4-methoxyphenyl)-2,3,4,5-tetrahydro-1,5-benzothiazepin-4-one |
---|
Traditional Name | desacetyldiltiazem |
---|
CAS Registry Number | 42399-40-6 |
---|
SMILES | COC1=CC=C(C=C1)[C@@H]1SC2=CC=CC=C2N(CCN(C)C)C(=O)[C@@H]1O |
---|
InChI Identifier | InChI=1S/C20H24N2O3S/c1-21(2)12-13-22-16-6-4-5-7-17(16)26-19(18(23)20(22)24)14-8-10-15(25-3)11-9-14/h4-11,18-19,23H,12-13H2,1-3H3/t18-,19+/m1/s1 |
---|
InChI Key | NZHUXMZTSSZXSB-MOPGFXCFSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as benzothiazepines. These are organic compounds containing a benzene fused to a thiazepine ring (a seven-membered ring with a nitrogen atom and a sulfur atom replacing two carbon atoms). |
---|
Kingdom | Organic compounds |
---|
Super Class | Organoheterocyclic compounds |
---|
Class | Benzothiazepines |
---|
Sub Class | Not Available |
---|
Direct Parent | Benzothiazepines |
---|
Alternative Parents | |
---|
Substituents | - Benzothiazepine
- Phenol ether
- Methoxybenzene
- Anisole
- Aryl thioether
- Phenoxy compound
- Alkyl aryl ether
- Alkylarylthioether
- Benzenoid
- Monocyclic benzene moiety
- Tertiary carboxylic acid amide
- Carboxamide group
- Secondary alcohol
- Tertiary aliphatic amine
- Tertiary amine
- Amino acid or derivatives
- Lactam
- Azacycle
- Carboxylic acid derivative
- Ether
- Thioether
- Organic nitrogen compound
- Alcohol
- Carbonyl group
- Hydrocarbon derivative
- Organic oxide
- Organopnictogen compound
- Amine
- Organic oxygen compound
- Organonitrogen compound
- Organooxygen compound
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | Not Available |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | Not Available | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatized |
---|
Spectra |
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Deacetyldiltiazem GC-MS (Non-derivatized) - 70eV, Positive | splash10-0a4l-6968000000-31d69e76cb441c8eb468 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Deacetyldiltiazem GC-MS (1 TMS) - 70eV, Positive | splash10-0ab9-9222300000-7e8a04693a2f019c8e3e | 2017-10-06 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Deacetyldiltiazem GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Deacetyldiltiazem Quattro_QQQ 10V, Positive-QTOF (Annotated) | splash10-00di-0309000000-4f78253225444d766ea1 | 2012-07-25 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Deacetyldiltiazem Quattro_QQQ 25V, Positive-QTOF (Annotated) | splash10-004i-1900000000-1318fea4679c168e8d97 | 2012-07-25 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Deacetyldiltiazem Quattro_QQQ 40V, Positive-QTOF (Annotated) | splash10-056s-0900000000-497dbcafd358c5226427 | 2012-07-25 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Deacetyldiltiazem 50V, Positive-QTOF | splash10-0ufr-0900000000-007ed6981e6a7674cea3 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Deacetyldiltiazem 20V, Positive-QTOF | splash10-00b9-0907000000-69fc05ea7be6f47f006b | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Deacetyldiltiazem 10V, Positive-QTOF | splash10-00di-0009000000-74bf9165b0dca218f517 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Deacetyldiltiazem 30V, Positive-QTOF | splash10-004i-0900000000-13b286bd59bfa08ca3f6 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Deacetyldiltiazem 40V, Positive-QTOF | splash10-0fb9-0900000000-b831c8e8da4a17767b72 | 2021-09-20 | HMDB team, MONA | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Deacetyldiltiazem 10V, Positive-QTOF | splash10-00di-2109000000-4f4d8b04f6fb38782b6c | 2017-09-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Deacetyldiltiazem 20V, Positive-QTOF | splash10-00di-5933000000-444752d9e318a3bdc1f1 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Deacetyldiltiazem 40V, Positive-QTOF | splash10-05fr-7900000000-727d8d2bd166506d75c5 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Deacetyldiltiazem 10V, Negative-QTOF | splash10-00di-0009000000-f7c98d8fc7f115cdcf72 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Deacetyldiltiazem 20V, Negative-QTOF | splash10-0ht9-0439000000-399a4eb4aff7fe5b62f9 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Deacetyldiltiazem 40V, Negative-QTOF | splash10-0zfr-1930000000-637a90a35ba5c3d96664 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Deacetyldiltiazem 10V, Negative-QTOF | splash10-00di-0009000000-7527d5f0c7e68d3bff36 | 2021-09-23 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Deacetyldiltiazem 20V, Negative-QTOF | splash10-0uk9-0198000000-ea4b553a352be3090135 | 2021-09-23 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Deacetyldiltiazem 40V, Negative-QTOF | splash10-0536-0691000000-10d11ae35e2a14440fab | 2021-09-23 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Deacetyldiltiazem 10V, Positive-QTOF | splash10-00di-0009000000-5a8213501fca1b97c1f6 | 2021-09-24 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Deacetyldiltiazem 20V, Positive-QTOF | splash10-00di-7209000000-9bcca83a828848518636 | 2021-09-24 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Deacetyldiltiazem 40V, Positive-QTOF | splash10-00di-5931000000-c443a5ed8d50f8d8e7e5 | 2021-09-24 | Wishart Lab | View Spectrum |
NMR SpectraSpectrum Type | Description | Deposition Date | Source | View |
---|
Experimental 1D NMR | 1H NMR Spectrum (1D, 600 MHz, H2O, experimental) | 2012-12-05 | Wishart Lab | View Spectrum | Experimental 2D NMR | [1H, 13C]-HSQC NMR Spectrum (2D, 600 MHz, H2O, experimental) | 2012-12-05 | Wishart Lab | View Spectrum |
|
---|
Biological Properties |
---|
Cellular Locations | - Membrane (predicted from logP)
|
---|
Biospecimen Locations | Not Available |
---|
Tissue Locations | |
---|
Pathways | |
---|
Normal Concentrations |
---|
| Not Available |
---|
Abnormal Concentrations |
---|
| Not Available |
---|
Associated Disorders and Diseases |
---|
Disease References | None |
---|
Associated OMIM IDs | None |
---|
External Links |
---|
DrugBank ID | Not Available |
---|
Phenol Explorer Compound ID | Not Available |
---|
FooDB ID | FDB023076 |
---|
KNApSAcK ID | Not Available |
---|
Chemspider ID | 82743 |
---|
KEGG Compound ID | Not Available |
---|
BioCyc ID | Not Available |
---|
BiGG ID | Not Available |
---|
Wikipedia Link | Not Available |
---|
METLIN ID | 2271 |
---|
PubChem Compound | 91638 |
---|
PDB ID | Not Available |
---|
ChEBI ID | Not Available |
---|
Food Biomarker Ontology | Not Available |
---|
VMH ID | Not Available |
---|
MarkerDB ID | Not Available |
---|
Good Scents ID | Not Available |
---|
References |
---|
Synthesis Reference | Not Available |
---|
Material Safety Data Sheet (MSDS) | Download (PDF) |
---|
General References | - Mahmood I, Sahajwalla C: Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. Clin Pharmacokinet. 1999 Apr;36(4):277-87. [PubMed:10320950 ]
- Vivian EM, Goebig ML: Slowing the progression of renal disease in diabetic patients. Ann Pharmacother. 2001 Apr;35(4):452-63. [PubMed:11302410 ]
- Gashti CN, Bakris GL: The role of calcium antagonists in chronic kidney disease. Curr Opin Nephrol Hypertens. 2004 Mar;13(2):155-61. [PubMed:15202609 ]
- Shamim W, Bakhai A, Yousufuddin M, Coats AJ: Increased urinary cortisol and androgen metabolites in a young female with hypertension: partial glucocorticoid resistance syndrome. Cardiology. 2000;93(1-2):131-2. [PubMed:10894920 ]
- Mousa O, Brater DC, Sunblad KJ, Hall SD: The interaction of diltiazem with simvastatin. Clin Pharmacol Ther. 2000 Mar;67(3):267-74. [PubMed:10741630 ]
- Abadin JA, Duran JA, Perez de Leon JA: Probable diltiazem-induced acute interstitial nephritis. Ann Pharmacother. 1998 Jun;32(6):656-8. [PubMed:9640485 ]
- Mies S, Massarollo PC, Figueira ER, Leitao RM, Raia S: Lower incidence of liver graft rejection in patients on diltiazem plus cyclosporine therapy. Transplant Proc. 1998 Jun;30(4):1437-8. [PubMed:9636582 ]
- Kawano Y, Makino Y, Okuda N, Takishita S, Omae T: Effects of diltiazem retard on ambulatory blood pressure and heart rate variability in patients with essential hypertension. Blood Press Monit. 2000 Jun;5(3):181-5. [PubMed:10915232 ]
- Zhao XJ, Jones DR, Wang YH, Grimm SW, Hall SD: Reversible and irreversible inhibition of CYP3A enzymes by tamoxifen and metabolites. Xenobiotica. 2002 Oct;32(10):863-78. [PubMed:12419016 ]
- Zucker ML, Budd SE, Dollar LE, Chernoff SB, Altman R: Effect of diltiazem and low-dose aspirin on platelet aggregation and ATP release induced by paired agonists. Thromb Haemost. 1993 Aug 2;70(2):332-5. [PubMed:8236144 ]
- Zhang XL, Xu B, Feng Y: Effects of diltiazem on down-regulation of lymphocyte beta-adrenoceptors in patients with chronic congestive heart failure. Acta Pharmacol Sin. 2000 Oct;21(10):927-30. [PubMed:11501046 ]
- Fukuoka Y, Tachibana T, Yasui A: Anaphylatoxin C3a induces rapid protein phosphorylation in guinea pig platelets. Immunopharmacology. 1994 Sep-Oct;28(2):95-104. [PubMed:8002292 ]
- Dimmitt DC, Bhargava VO, Arumugham T, Eller M, Weir SJ: Relative bioavailability of Cardizem CD and Tiazac controlled-release diltiazem dosage forms after single and multiple dosing in healthy volunteers. Am J Ther. 1998 May;5(3):173-9. [PubMed:10099056 ]
- Sperschneider H, Wagner C, Korn A, Christians U: [Effect of diltiazem on concentration of cyclosporin metabolites in Sandimmune and Neoral treated kidney transplant patients]. Med Klin (Munich). 1997 Oct 15;92(10):589-96. [PubMed:9446006 ]
- Morimoto Y, Kemmotsu O, Gando S, Shibano T, Shikama H: The effect of calcium channel blockers on cerebral oxygenation during tracheal extubation. Anesth Analg. 2000 Aug;91(2):347-52. [PubMed:10910846 ]
- Mayhew BS, Jones DR, Hall SD: An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab Dispos. 2000 Sep;28(9):1031-7. [PubMed:10950845 ]
- Odawara A, Kikkawa K, Katoh M, Toryu H, Shimazaki T, Sasaki Y: Inhibitory effects of TA-993, a new 1,5-benzothiazepine derivative, on platelet aggregation. Circ Res. 1996 Apr;78(4):643-9. [PubMed:8635222 ]
- Jones TE, Morris RG: Pharmacokinetic interaction between tacrolimus and diltiazem: dose-response relationship in kidney and liver transplant recipients. Clin Pharmacokinet. 2002;41(5):381-8. [PubMed:12036394 ]
- Tateishi T, Ohashi K, Fujimura A, Ebihara A: The influence of diltiazem versus cimetidine on propranolol metabolism. J Clin Pharmacol. 1992 Dec;32(12):1099-104. [PubMed:1487547 ]
- Roth M, Eickelberg O, Kohler E, Erne P, Block LH: Ca2+ channel blockers modulate metabolism of collagens within the extracellular matrix. Proc Natl Acad Sci U S A. 1996 May 28;93(11):5478-82. [PubMed:8643600 ]
- Du Souich P, Lery N, Lery L, Varin F, Boucher S, Vezina M, Pilon D, Spenard J, Caille G: Influence of food on the bioavailability of diltiazem and two of its metabolites following the administration of conventional tablets and slow-release capsules. Biopharm Drug Dispos. 1990 Mar;11(2):137-47. [PubMed:2328299 ]
- Shibata N, Morita K, Ono T, Nishikawa S, Kinoshita M, Kawakita S, Takada K, Muranishi S, Shimakawa H: Effects of diltiazem on rheological properties of human blood. J Pharmacobiodyn. 1988 Mar;11(3):175-80. [PubMed:3411434 ]
|
---|